speaking quarter following with Thank you, in today Robert, history. the everyone. and Biopharma's you welcome, be exceptional to Aytu year excited an We're and strongest
to with prescriptions our year. for promoted total XX% last annual having of market core for closed, on fiscal press increased the the $XXX.X year. results Gross the the Rx million, all-time we can revenues our a achieved release for margins compared prescriptions XX% year issued over XXXX from had all XXX,XXX to segment after products finished see record financial you last written strong note As we in high
to quarter, for adjusted an while $X.X from improvement fourth during year also due company-wide of the fiscal down impairments year net significant our EBITDA full ago have segment, which $X.X of the XXXX. fourth impairments, quarter part the been And Health net would EBITDA the million the of our And quarterly set we improvement wind of positive of way, for income Consumer without the million. was stage adjusted in negative QX Positive slightly million million. as income several fiscal 'XX $XX.X taken $X.X by for into those translated
of Rx of Karbinal Adzenys antihistamine This Cotempla of our dramatic results our along multivitamins, comprised operating transformation Rx ER. is segment our due product which our XR-ODT our strength the lines, with to is and pediatric and XR-ODT
and while ADHD is shortages, benefiting to This growth improvement operating execution from a in and experience fiscal products setting tailwinds all Our continue internal all strong the products improvements. field I'll stimulant this of in our more moment. are from touch stage on margin and the prescription ongoing continued XXXX. for
plan transformation of light our sustainability, fruition. not undertaken was a the current development and to to particularly I'm company plan place operating of results a happen and market strategic our pivot coming financial pathway overnight, clinical to see deliberate pleased The environment. in from It indefinitely on away did the to
but shareholders. announced time efforts one internally the last we research and that knew cash expenses and those that fund difficult with we decision, our minimize the long-term best programs in in X a pipeline partnership. through such This the suspended to companies was was flow interest Step its we was generated or plan October development when a can of strategic indefinitely until
through EBITDA while year implemented negative segment our fiscal on was segment or this our adjusted Health deemphasizing that our growing profitable discontinuing of Health on commercial in component some To perspective when segment strategy, June had announced of this and put second million. efforts focus during Rx it. monetizing of we we Consumer 'XX either our The plan Consumer that would $X.X
clinical this had of EBITDA for adjusted quarter which year, Our really $X.X million. was a negative only development operational program,
looking EBITDA of X at $X.X adjusted segments. we're negative million So these a across
our note all had had Rx the contrast, overhead, $X.X adjusted posted our of In corporate segment, -- year. I'll which positive for of EBITDA supports million
we've profitability. and on Going the focusing forward, is positive ongoing growing, EBITDA poised exclusively an consistent operating by to our highlighted has business Rx that's company achieve segment, and
inventory as expenses. will remaining As to the our XXXX, becomes selling company, go-forward minimizing off segment we carefully by look Rx segment down its Consumer Health look to we and wind its fiscal our
minimal We expect neutral fiscal EBITDA segment XXXX. in this to from be adjusted to there impact our to
The strategic segment should the XXXX result Consumer barring adjusted deemphasis and noncash adjusted our any exits focus impacts on GAAP Health not closing on anticipate EBITDA year fiscal the will improvement but company-wide in on actions the with unforeseen that Consumer fiscal in and profitability.
We prescription company-wide facility do some the impact residual our EBITDA. write-downs of Health segment, associated products XXXX Texas are and these manufacturing
is take forward, business moment Let's to segment. into our core further Rx dive our a what going
As platform utilize mentioned of modified Orange with extended-release held Book-listed novel release ADHD first disintegrating the for and Cotempla beginning, branded the microparticle respectively. and amphetamine category and tablets medications only technology multiple our the XR-ODT delivery at ADHD, patents. orally each and proprietary XR-ODT, treatment methylphenidate the we Adzenys FDA-approved drug operate in These
On includes and formulations fluoride infants the fluoride-based to available pediatric deficiency. various for our children portfolio side, our in multivitamins
suspension Karbinal also conditions carbinoxamine older. antihistamine ER, patients and to for treat extended-release market We X years allergic based numerous an indicated
patient and benefits strong branded protection. clinical property These the competitive intellectual have products serve well-established features and products distinct pediatric and generic over markets and offer
Net about ADHD for for quarters up XX% the trends growth our quarter revenue the year. ADHD into including we've was market. first. the up ADHD and persist, X% long-term go in for few products last Let's The the fiscal in overall talked
stimulant disruptions supply see adults Adderall disruptions in published the this at These The discontinued various the increase of from abounds shortages to being XR point. as as late. shortages an several altogether generic continuing continue for around children impact diagnoses daily products and and and news in widespread new almost these with editorials well stimulant We of methylphenidate products. as articles ongoing with are being
an done demand. impact opportunity having by on presented market job We've disruptions have the our maintained operations, ADHD this exceptional ongoing meet to while throughout these our events to expect we i.e., and to no continue growing the supply negative demand growth maximizing supply meet ever-increasing market
quarters the new competitive have Adzenys. prescribers way past over their number both We Adzenys to share, patients believe and enabled to propelling disruptions mind find of market gain to supply the and
our for representing the When new writers year at doubled illustrate 'XX from X consider To writers by new writers. XX%. that our grew 'XX, fiscal have this, our of growth total we with looking over writers XX% to than writer new Adzenys more fiscal Adzenys years,
We Cotempla writers XX% Cotempla writers. almost XX% of representing have by over almost that increased writers total time new same with frame
as bioequivalent reminder, a approved is Adzenys Adderall to As XR.
to are remains continued year coupled Cotempla RxConnect the generally commercial during for So told, them.
The additional same as and disruptions, our clinicians Adzenys for the sticky ongoing. up fiscal impact compared fourth with quarter scripts from supply continue to the prescriptions and Aytu XX% look we that is were to year the Adzenys leverage well share work over a at year-to-date execution team driving shipments we units All Also, levels continues. capture if this fiscal strong up record to prescriptions as the 'XX, brand ago. period XX.X% of our fiscal hold we up our so are the the the drove new continue expect drugs extended-release year. and on XX.X% sales and share fourth momentum amphetamine positioned to platform, last shortage here with for same our to as And with factory The the patients far ADHD both in period are quarter.
dynamics April in to -- this last closely it net we We bears increase would keep be to last up implemented X. for more that growth costs, customary revenues rising in and a quarter, with to itself us to we This script and reminding discussed this market responsive but adjustment ADHD channel price resulted with order aligned, did. products out quarter, our being quarter a onetime which it indicated and even effective for
changes we've that do and patient to since It's deductibles undertaken improvement calendar traction, nets. year patient initiatives deductibles margins the savings that beginning worth gross at of to insurance continue the and impact the we doing. overall are reminding to We've offers seen the improved March resetting and and underlying indeed see the gain calendar the they quarter see of payer which continue numerous are from our impact the our year, everyone met and these the expect as through
both of also we're improve we're outsourced the to seeing manufacturing Adzenys the from side, Beyond profitability the and success implementing through initiatives Cotempla. sales
products. to we've ADHD change of improve this gross margins As discussed, further expected is our
let or PAS we update FDA, production to process. supplement In submitted to Cotempla our on the us approval you third-party to approved, of the me manufacturer. transfer which enables So once Cotempla this July, prior the
We late which by calendar 'XX. 'XX the enable calendar approval expect of or a X-month PAS FDA review should submission, early
we As company's FDA manufacturer. approval of to begun previously Adzenys PAS transfer you the site production and already received may recall, contract Adzenys shifting the have
the entire the tremendous point, calendar applaud advance transfer of site for improvements to work brands. Cotempla ADHD this these approval, team ADHD to This a in the to So we get hard has effort team's expect I in advancing assuming margin been realizing we the the brands 'XX. important us start and
we're Let's XX% XX% increasing are growth as transition fiscal product's continued that quarter revenue trajectory. ongoing growth commercial The tailwinds platform our to portfolio our pleased year, and was pediatric pediatric for up key for the prescription for the Net the now. execution with. in up Aytu RxConnect remarkable product the portfolio and improvements well These leverage. drivers are awareness here as providing our very
The Karbinal the these time grown increased prior numbers to Scripts platform over Neos. products pediatric XX% surely was RxConnect platform, prescribers from leverage, X we to over XXX% these almost ER years prescriptions affords of the years. number which same multivitamins over the developed XXX% being for that multivitamin of X over added grew RxConnect number significantly. that previously out. the we ago, grew have have our us and Since RxConnect prescribers at added bear products frame. to Further,
of yield profile. as a of currently we multivitamin extension of line profile acid over with It profile, market. We stability enhanced last launching body Arcofolin's ready other molecular that improved and assay the bit and folate ion a low an improved purity Metafolin also an offers has L-methylfolate novel the counter a water also quarter. Arcofolin ingredient on an higher levels L-methylfolate. solubility forms overall than Arcofolin. weight discussed excellent content are available this folic low a water
those enhance IP We Arcofolin we from will differentiation to addition The further to adoption products transition provides growth multivitamin look and and products. and to Arcofolin our profile, of other also continued forward portfolio. the unique extends protection product the the brand's of believe lines pediatric
from big can seen changes downdraft but multivitamin rather, payer single approaches some prescribing payer prescriber believe broaden and through underway in have this we're already this payer to are current We've and through we're of begun with the to These payer, reimbursement outside deepen specifically the offset growth get writers we both efforts traction. well and taking real and a starting we several novel base. category, to our
And again tremendous that continues growth. the ADHD remind I'll its you portfolio
the So all put we're about portfolio how was and excited performing together.
has RxConnect we we're category the enhanced achieving from across brands. both achieve with our ADHD This segment. driven leverage platform execution with our elevated pleased by I'm continue through organization, tailwinds strong performance to the sales traction and Rx our Overall, been
is margins, in strong and Rx that core as into draw One income. move you think rates expanding double-digit down net and business with is achieving it's 'XX the positive our EBITDA your going fiscal revenues what on With growth, about and our as Health segment of Aytu's forward, growing would attention segment, gross we adjusted beyond. at net Consumer I wind profile to financial prescription the closing
was for XX% In quarter. fact, margin Rx the income for $X.X was a adjusted operations $X.X and quarter representing fourth from million, EBITDA the the for EBITDA million, segment adjusted
great the near And bottom every don't while in prospects we of have going that confidence and for expect segment term, its necessarily in quarter strength. this growing EBITDA level we line forward consistent
create also strength the mind numbers. be in the You'll P&L. on that may our closed quarterly down full small will EBITDA the reflected that some that need company-wide once drag keep we've we as But wind of Rx the Consumer to business, segment in segment, Health
are we We this believe And attractive. is believe applying should emphasis prescription business the the very segment it forward, we to shareholder exclusively with value. enhance going
Mark? turn the With numbers. our that over CFO, overview, some color to to additional let me Mark it to Oki, add
